The technology of the Company was initially developed in 2002 to 2005 in the laboratories of Dr. Sylvain Chemtob at CHU Ste. Justine, an affiliated hospital of the University of Montreal. Dr. Chemtob, a prominent clinical and academic researcher, and Christiane Quiniou, a graduate student in his lab, conducted much of the early work to support the Module X technology. The Company’s incorporation in December 2005 was managed by Gestion Univalor, L.P., an entity whose mission is the transfer to industry of intellectual properties from the Université de Montréal, its affiliated schools and most of its affiliated hospitals.

Research was funded from 2002 to 2009 under the following financial instruments:

In July 2009, Allostera raised $17M in equity financing with the purpose of evaluating APG2305 in human clinical trials and developing the concept of the Module X platform to demonstrate that Allostera can consistently develop orally active, commercializable Allosteramers™ against multiple targets.